Radiotherapy News and Research

RSS

Radiation therapy (in North America), or radiotherapy (in the UK and Australia) also called radiation oncology, and sometimes abbreviated to XRT, is the medical use of ionizing radiation as part of cancer treatment to control malignant cells (not to be confused with radiology, the use of radiation in medical imaging and diagnosis).

Positive interim results from CTI's OPAXIO-TMZ phase II trial on malignant brain tumors presented at ASCO

Cell Therapeutics, Inc. announced encouraging interim results of a phase II clinical study of OPAXIO combined with temozolomide and radiotherapy in patients with newly diagnosed high-grade malignant brain tumors.

6 Jun 2011

Ipsen decides to assess development of Irosustat in combination with hormonal therapies

Ipsen today announced its decision to assess the alternative development of Irosustat (BN 83495) in combination with other hormonal therapies. This decision is based on the futility analysis from the proof-of-concept trial phase II clinical study carried out in Europe in monotherapy in endometrial cancer, and on the phase I/II clinical study results obtained in metastatic prostate and breast cancers.

6 Jun 2011

Results from HSPPC-96 Phase 2 study against recurrent gliobastoma presented at ASCO 2011

In data presented at The American Society of Clinical Oncology (ASCO) Annual Meeting, cancer researchers found that the brain tumor vaccine HSPPC-96 for treating recurrent gliobastoma (GBM) has a favorable safety profile and extends survival by two to three times more than the current median survival rate.

4 Jun 2011

ASTRO to honor two radiation oncologists with 2011 Gold Medal award

The American Society for Radiation Oncology has selected K. Kian Ang, MD, PhD, FASTRO, and Bernard Cummings, MB, ChB, FASTRO, as the Society's 2011 Gold Medal recipients.

26 May 2011

CRT, Cancer Research UK and Centella partner to launch clinical development of CEN-209

Cancer Research UK and Cancer Research Technology - the charity's development and commercialisation arm - have partnered with Centella Therapeutics, Inc. of Palo Alto, California, to develop, manufacture and trial a promising new drug, CEN-209 in cancer patients with solid tumours.

25 May 2011

DFG to fund 60 million euros for 18 new Research Training Groups

With the aim of further strengthening early-career research in Germany, the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is to establish 18 new Research Training Groups.

21 May 2011

RTOG reports on largest trial for newly diagnosed glioblastoma

RTOG reports on the largest trial to-date for patients with newly diagnosed glioblastoma demonstrating the importance and feasibility of prospective molecular analysis of tumor tissue although finding that patients received no additional benefit from dose-intensive temozolomide as compared to standard adjuvant temozolomide after combined temozolomide and radiotherapy.

20 May 2011

CEL-SCI initiates global Multikine Phase III trial for head and neck cancer in Russia

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, in Russia at the State Budgetary Healthcare Institution of Sverdlovsk Region - Sverdlovsk Regional Oncology Center in Ekaterinburg, Russia.

20 May 2011

Concord Medical first quarter total net revenues increase 14.7% to $13.3 million

Concord Medical Services Holdings Limited, the operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced its unaudited consolidated financial results for the first quarter ended March 31, 2011.

18 May 2011

CITN selects Cytheris' CYT107 for initial clinical trials at network institutions

Cytheris SA and the Cancer Immunotherapy Trials Network, a new initiative in immunotherapy funded by the National Cancer Institute with its Central Operations and Statistical Center headquartered at Fred Hutchinson Cancer Research Center, Seattle, Washington, today announced the selection of recombinant human interleukin-7, the investigational multifunctional cytokine under development by Cytheris, as one of the first immunotherapeutic agents proposed for initial clinical trials at network institutions.

18 May 2011

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Canada

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, in Canada at St. Joseph's Healthcare - Hamilton, Ontario.

18 May 2011

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Poland

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, at the Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie, Warsaw, Poland, the first clinical site in Poland and the first center in the EU.

13 May 2011

Researchers untangle two distinct ways in which tumor-suppressor protein works

Researchers at the Stanford University School of Medicine have untangled two distinct ways in which a common, naturally occurring "tumor-suppressor" protein works.

13 May 2011

INESC Porto, FC and FMUP to hold international seminar on breast cancer local treatment

The international seminar "Turning Subjective Into Objective: Cosmetic Breast Assessment of Local Treatment" will take place on 13th May starting at 9.15am. The event is organised by the Champalimaud Foundation, the Faculty of Medicine of the University of Porto and the Institute for Systems and Computer Engineering of Porto.

12 May 2011

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, the Centre Léon Bérard, the major cancer research and treatment center for the Rhône-Alpes region of France, and ImmunID Technologies SAS, a diagnostic company specialized in innovative immunomonitoring tests and services, today announced initiation of a Phase IIa clinical trial that will evaluate multiple combinations of recombinant human interleukin-7, the investigational multifunctional cytokine under development by Cytheris, and a chemotherapeutic agent, XELODA, in the treatment of metastatic breast cancer.

11 May 2011

BioAlliance Pharma enters license deal with Sosei to commercialize Loramyc in Japan

BioAlliance Pharma, a company dedicated to specialty and orphan pharma products in oncology and supportive care, today announced that it has entered into an exclusive licensing agreement with Sosei Co. Ltd. for commercialization rights in Japan for Loramyc muco-adhesive buccal tablet.

11 May 2011

Sosei acquires rights to Loramyc in Japan from BioAlliance Pharma

Sosei Group Corporation, the biopharmaceutical company, today announces that Sosei Co., Ltd., its wholly owned Japanese subsidiary, acquired development and commercialization rights to Loramyc (miconazole Lauriad) in Japan from BioAlliance Pharma.

11 May 2011

Hitachi to provide Mayo Clinic with two sets of proton beam therapy systems

Hitachi, Ltd. today announced that it has entered into an agreement to provide Mayo Clinic with its proton beam therapy (PBT) system. This next-generation technology has spot scanning capability for treating certain forms of cancer. The agreement includes PBT system maintenance for both facilities for 10 years following completion of the systems' installation.

10 May 2011

Seventh Annual Neuro-Oncology Symposium to be held at Hackensack University Medical Center

The John Theurer Cancer Center at Hackensack University Medical Center will host the Seventh Annual Neuro-Oncology Symposium on Friday, May 20 from 7:30am - 1:00pm. This continuing medical education conference will present the latest neuro-oncology trends by leaders in the field.

10 May 2011

Thomas Jefferson University receives award to develop novel radiation drugs

Shortly before Japan's devastating nuclear incident, researchers at Thomas Jefferson University and Hospitals received an award to find novel drugs to treat people exposed to dangerous amounts of radiation in the wake of a nuclear terrorist attack or a nuclear accident.

5 May 2011

Radiotherapy News and Research

Further Reading

Positive interim results from CTI's OPAXIO-TMZ phase II trial on malignant brain tumors presented at ASCO

Ipsen decides to assess development of Irosustat in combination with hormonal therapies

Results from HSPPC-96 Phase 2 study against recurrent gliobastoma presented at ASCO 2011

ASTRO to honor two radiation oncologists with 2011 Gold Medal award

CRT, Cancer Research UK and Centella partner to launch clinical development of CEN-209

DFG to fund 60 million euros for 18 new Research Training Groups

RTOG reports on largest trial for newly diagnosed glioblastoma

CEL-SCI initiates global Multikine Phase III trial for head and neck cancer in Russia

Concord Medical first quarter total net revenues increase 14.7% to $13.3 million

CITN selects Cytheris' CYT107 for initial clinical trials at network institutions

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Canada

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Poland

Researchers untangle two distinct ways in which tumor-suppressor protein works

INESC Porto, FC and FMUP to hold international seminar on breast cancer local treatment

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

BioAlliance Pharma enters license deal with Sosei to commercialize Loramyc in Japan

Sosei acquires rights to Loramyc in Japan from BioAlliance Pharma

Hitachi to provide Mayo Clinic with two sets of proton beam therapy systems

Seventh Annual Neuro-Oncology Symposium to be held at Hackensack University Medical Center

Thomas Jefferson University receives award to develop novel radiation drugs

Cancer Research - Second Edition eBook

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News